GSK 6-K
GSK plc (GSK)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2025
Commission File Number 001-15170
GSK plc
(Translation of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc
Results of 25th Annual General Meeting
GSK plc ('GSK') held a hybrid Annual General Meeting ('AGM') at 2.30pm on Wednesday 7 May 2025 at The Landmark London, 222 Marylebone Road, London, NW1 6JQ. Shareholders were able to join the meeting in person or virtually via the Lumi AGM website and Zoom.
All valid proxy votes (whether submitted electronically or in hard copy form) were included in the poll taken at the meeting.
All 25 resolutions were passed and decided upon by a poll. The table below shows the results for each resolution. The full text of the resolutions is contained in the Notice of AGM published on 24 March 2025, which is available on GSK's website at www.gsk.com.
| Resolution | Total votes for(1)(2) | % | Total votes against(2) | % | Total votes cast | % of Issued Share Capital voted(3) | Votes withheld(4) | |
|---|---|---|---|---|---|---|---|---|
| 1 | Receive<br>and adopt the 2024 Annual Report | 3,031,647,740 | 99.82 | 5,472,209 | 0.18 | 3,037,119,949 | 73.91% | 12,204,390 |
| 2 | Approve<br>the Annual report on remuneration | 2,810,183,626 | 92.46 | 229,176,108 | 7.54 | 3,039,359,734 | 73.97% | 9,979,421 |
| 3 | Approve<br>the Remuneration policy | 2,786,567,742 | 93.10 | 206,384,696 | 6.90 | 2,992,952,438 | 72.84% | 56,376,703 |
| 4 | Election<br>of Dr Gavin Screaton | 3,040,206,238 | 99.89 | 3,385,136 | 0.11 | 3,043,591,374 | 74.07% | 5,719,426 |
| 5 | Re-election<br>of Sir Jonathan Symonds | 2,947,917,394 | 98.40 | 48,075,530 | 1.60 | 2,995,992,924 | 72.91% | 53,319,043 |
| 6 | Re-election<br>of Dame Emma Walmsley | 3,038,248,728 | 99.82 | 5,613,533 | 0.18 | 3,043,862,261 | 74.08% | 5,444,311 |
| 7 | Re-election<br>of Julie Brown | 3,034,344,765 | 99.69 | 9,515,889 | 0.31 | 3,043,860,654 | 74.08% | 5,460,463 |
| 8 | Re-election<br>of Elizabeth McKee Anderson | 2,941,679,748 | 96.64 | 102,161,424 | 3.36 | 3,043,841,172 | 74.08% | 5,465,676 |
| 9 | Re-election<br>of Charles Bancroft | 2,956,308,387 | 97.13 | 87,450,752 | 2.87 | 3,043,759,139 | 74.07% | 5,553,709 |
| 10 | Re-election<br>of Dr Hal Barron | 3,039,339,475 | 99.85 | 4,466,176 | 0.15 | 3,043,805,651 | 74.08% | 5,489,801 |
| 11 | Re-election<br>of Dr Anne Beal | 2,955,431,838 | 97.09 | 88,492,673 | 2.91 | 3,043,924,511 | 74.08% | 5,388,566 |
| 12 | Re-election<br>of Wendy Becker | 2,933,164,994 | 96.36 | 110,745,350 | 3.64 | 3,043,910,344 | 74.08% | 5,400,009 |
| 13 | Re-election<br>of Dr Harry C Dietz | 3,039,383,688 | 99.86 | 4,369,000 | 0.14 | 3,043,752,688 | 74.07% | 5,560,851 |
| 14 | Re-election<br>of Dr Jeannie Lee | 3,039,577,387 | 99.86 | 4,161,377 | 0.14 | 3,043,738,764 | 74.07% | 5,574,652 |
| 15 | Re-election<br>of Dr Vishal Sikka | 3,038,858,707 | 99.84 | 4,756,490 | 0.16 | 3,043,615,197 | 74.07% | 5,688,803 |
| 16 | Re-appointment<br>of the auditor | 3,025,673,462 | 99.89 | 3,223,574 | 0.11 | 3,028,897,036 | 73.71% | 20,430,064 |
| 17 | Remuneration<br>of the auditor | 3,039,931,435 | 99.88 | 3,782,302 | 0.12 | 3,043,713,737 | 74.07% | 5,591,584 |
| 18 | Authority<br>for the company to make donations to political organisations and<br>incur political expenditure | 2,946,755,927 | 99.01 | 29,581,561 | 0.99 | 2,976,337,488 | 72.43% | 72,977,673 |
| 19 | Authority<br>to allot shares | 2,899,903,495 | 95.30 | 143,133,156 | 4.70 | 3,043,036,651 | 74.06% | 6,282,441 |
| 20 | Disapplication<br>of pre-emption rights - general power(5) | 2,941,521,597 | 96.72 | 99,811,731 | 3.28 | 3,041,333,328 | 74.02% | 7,942,085 |
| 21 | Disapplication<br>of pre-emption rights - in connection with an acquisition or<br>specified capital investment(5) | 2,962,038,875 | 97.39 | 79,351,038 | 2.61 | 3,041,389,913 | 74.02% | 7,904,048 |
| 22 | Authority<br>for the company to purchase its own shares(5) | 3,036,538,826 | 99.83 | 5,280,936 | 0.17 | 3,041,819,762 | 74.03% | 7,499,989 |
| 23 | Exemption<br>from statement of senior statutory auditor's name | 3,022,840,749 | 99.74 | 7,951,051 | 0.26 | 3,030,791,800 | 73.76% | 18,502,136 |
| 24 | Authority<br>for reduced notice of a general meeting other than an<br>AGM(5) | 2,863,892,275 | 94.11 | 179,242,127 | 5.89 | 3,043,134,402 | 74.06% | 6,172,307 |
| 25 | Approve<br>the adoption of the GSK Share Value Plan | 2,972,805,515 | 99.56 | 13,033,137 | 0.44 | 2,985,838,652 | 72.67% | 63,503,752 |
Notes:
(1) The "for" votes include those giving the Chair discretion.
(2) Votes "for" and "against" are expressed as a percentage of the total votes cast.
(3) The Company's issued share capital as at 2 May 2025 consisted of 4,109,037,095 shares of 31 ¼ pence each ('Ordinary Shares') excluding Ordinary Shares held in Treasury. Every shareholder has one vote for every Ordinary Share held.
(4) A "vote withheld" is not a vote in law and is not counted in the calculation of the proportion of votes "for" or "against" a resolution.
(5) Indicates Special Resolutions requiring a 75% majority of votes cast.
The following table provides further information on participation in the AGM:
| GSK's 25th AGM<br><br><br>(Hybrid meeting)<br><br><br>(2025) | GSK's<br>24th AGM<br><br>(Hybrid<br>meeting)<br><br>(2024) | |
|---|---|---|
| Issued share capital (excluding Treasury Shares) | 4,109,037,095 | 4,314,108,510 |
| Total votes cast and votes withheld lodged as a % of GSK's issued<br>share capital (excluding Treasury Shares) | 74.21% | 73.11% |
| Total shareholder population | 86,241 | 60,448 |
| Total number of proxies lodged | 3,743 | 2,886 |
| Number of shareholders in attendance | 130 in<br>person<br><br>25<br>participated virtually | 125 in<br>person<br><br>38<br>participated virtually |
| % of shareholders who lodged proxies | 4.34% | 4.77% |
The above poll results will shortly be available on the company's website at www.gsk.com.
In accordance with Listing Rule 6.4.2 of the Financial Conduct Authority's (FCA) Listing Rules, a copy of the resolutions, other than those concerning ordinary business, will be submitted to the FCA and will, in due course, be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
V A Whyte
Company Secretary
7 May 2025
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
| GSK plc | |
|---|---|
| (Registrant) | |
| Date: May<br>07, 2025 | |
| By:/s/ VICTORIA<br>WHYTE<br><br>-------------------------- | |
| Victoria Whyte | |
| Authorised<br>Signatory for and on | |
| behalf<br>of GSK plc |